Natco Pharma, one of the few Indian companies to venture into new drug discovery research on February 26 announced the launch of Brivaracetam tablets under brand BRECITA in India.
Brivaracetam is indicated towards treatment of epilepsy.Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact.
NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of Rs 25 and Rs 35 per tablet respectively.
Epilepsy patients in India are estimated to be between 5-10 million, as per GEMIND guidelines.
Shares of the company gained Rs 1.8, or 0.22%, to trade at Rs 804. The total volume of shares traded was 12,019 at the BSE (12.17 p.m., Friday).